RNDO-564

· Rondo Therapeutics

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for RNDO-564, covering 2026-03-23 to 2026-03-23. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 [Phase 1]

See pricing